Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026

Lundbeck reported record FY2025 results with revenue of DKK 24,630m (+13% CER; +12% DKK) and EBITDA of DKK 7,140m (+38% CER), while adjusted EBITDA rose to DKK 7,881m (+24% CER). Performance was driven by U.S. growth (DKK 13,287m, +21% CER) and strength in strategic brands—Rexulti DKK 6,205m (+23% CER) and Vyepti DKK 4,476m (+59% CER)—partly offset by declining Brintellix/Trintellix and higher R&D plus an impairment tied to a planned divestment. EPS was DKK 3.22 (adjusted EPS DKK 5.26) and the Board proposed a DKK 1.15/share dividend (+21%); management highlights pipeline progress and regulatory milestones in Asia, supporting continued growth into 2026.

Analysis

Market structure: Lundbeck (LUN.CO) is a clear winner—2025 revenue +13% CER and adjusted EBITDA +24% CER show expanding pricing power for strategic brands (Rexulti, Vyepti) and US market leverage (US = DKK 13.3bn, ~54% of sales). Competitors in the aCGRP migraine class (Amgen/Novartis/Lilly franchises) face a structural share-loss risk in patients who failed prior SC agents if Vyepti gains traction in IV-switch populations; payers will test price/value but near-term demand is confirmed by INFUSE real-world data.

Risk assessment: Key tail risks are regulatory setbacks in Japan/China/Korea (decisions pending 2026), an adverse safety signal for Vyepti or bexicaserin, or manufacturing/legal issues exposed by the Italy site divestment. Immediate risk (days-weeks) centers on conference-call guidance and FX moves; short-term (3–9 months) on approval decisions and Q1’26 results; long-term (12–36 months) on 5–6 mid/late-stage assets converting to revenue. Watch net-debt/EBITDA, R&D burn and dividend payout ratio (>21% increase) as liquidity stress indicators.

Trade implications: Tactical long Lundbeck equity exposure is warranted into H1–H2 2026 approvals and multiple pipeline readouts; use position sizing 2–3% NAV and hedge via short biotech ETF (XBI) or put protection. Options: 6–9 month call-debit spread (buy ATM, sell 25–35% OTM) to cap cost while capturing regulatory upside. Rotate from high-volatility small-cap neuro/epilepsy names into European specialty pharma and investment-grade pharma credit; tighten exposure if net-debt/EBITDA >2.5x or adjusted EBITDA growth <10% next quarter.

Contrarian angles: Consensus may overestimate durable pricing for an IV drug vs convenient SC injectables—payer resistance and infusion logistics cap peak share in primary prevention. The market may underprice manufacturing/reshaping costs signaled by the Italy impairment; a modest slowdown in free cash flow could force dividend re-rating. Historical analogue: single-product growth stories that expanded quickly but retrenched after a late-stage pipeline miss—monitor early R&D milestones closely and be ready to reduce positions on any negative readouts.

Key Decisions for Investors

• Establish a 2–3% NAV long position in Lundbeck (LUN.CO) over the next 2–6 weeks, targeting +20–30% upside into H2 2026 (pipeline/approval catalysts). Place stop-loss at -12% and cut position if net-debt/EBITDA exceeds 2.5x or next-quarter adjusted EBITDA growth drops below 10%.
• Buy a 6–9 month call-debit spread on LUN.CO: long ATM call and sell 25–35% OTM call sized to 1–1.5% NAV to capture approval/INFUSE momentum while limiting premium decay; close on approval announcements or 30% move up.
• Pair trade: go long LUN.CO 1.5% NAV and short XBI (SPDR S&P Biotech ETF) 1% NAV to express rotation into specialty, reducing beta to small-cap biotech; rebalance monthly and unwind if XBI outperforms by >15% in 30 days.
• Reduce/avoid exposure to small-cap epilepsy/neuro names (tickers: e.g., small-cap speculative ALTZ-like names) and reallocate proceeds to Lundbeck and investment-grade pharma credit; redeploy if bexicaserin pivotal data are positive—add only after 2 consecutive favorable readouts.
• Monitor three binary catalysts closely within 30–180 days: (1) MHLW/NMPA/ROK decisions on eptinezumab (if approved, add 0.5–1% NAV), (2) INFUSE 12-month peer-reviewed publication or payer formulary wins (if confirmed, roll up calls), (3) any regulatory CRL or major safety signal (if occurs, liquidate equity exposure immediately).